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Abstract: Levo-tetrahydropalmatine (l-THP) is an active constituent of herbal 
preparations containing plant species of the genera Stephania and Corydalis 
and has been approved and used in China for a number of clinical indications 
under the drug name Rotundine. The pharmacological profile of l-THP, which 
includes antagonism of dopamine D1 and D2 receptors and actions at 
dopamine D3, alpha adrenergic and serotonin receptors, suggests that it may 
have utility for treating cocaine addiction. In this review, we provide an 
overview of the pharmacological properties of l-THP and the evidence 
supporting its development as an anti-addiction medication. The results of 
preclinical work demonstrating that l-THP attenuates cocaine’s 
reinforcing/rewarding effects and reinstatement in rat models of cocaine 
relapse are summarized, and the outcomes of studies demonstrating efficacy 
in human addicts are described. Finally, an overview of the safety profile of l-
THP is provided and challenges associated with FDA approval of l-THP are 
discussed. 
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Introduction 
Despite intense drug development efforts, the treatment of 
cocaine addiction persists as an unmet medical need for which there is 
no currently available FDA-approved medication. The impact of cocaine 
addiction on society is tremendous, with costs likely in the tens of 
billions of dollars [1]. While sizable, the monetary cost of cocaine 
addiction is overshadowed by the enormous toll that it takes on the 
individual, family, and community. The complexity of cocaine’s 
neuropharmacological actions (as a monoamine uptake blocker, 
cocaine acutely promotes the actions of dopamine, norepinephrine and 
serotonin leading to widespread effects in the brain) and the multi-
faceted nature of addiction make treatment a significant challenge. 
Current treatment strategies consist primarily of cognitive/behavioral-
based interventions and have limited efficacy. It is generally 
recognized that any significant therapeutic advances will likely stem 
from the identification and/or development of medications that target 
the neuropathological consequences of long-term cocaine abuse. 
Traditionally, drug development approaches aimed at treating 
cocaine addiction have been based on the ability of candidate 
compounds to attenuate the subjective or positive 
reinforcing/rewarding effects of cocaine. However, while mitigating 
these effects of cocaine may curb its use, it has become clear that that 
a critical attribute of any effective treatment will be its ability to 
prevent the sudden onset of drug craving and resultant relapse that 
emerges, often unpredictably, even after extended periods of 
abstinence from drug use. Since it appears that the neurobiological 
processes that underlie craving and relapse are largely distinct from 
those that mediate cocaine’s reinforcing/subjective effects, it can be 
argued that optimal treatment may require a “cocktail approach” 
involving multi-drug therapy or medications with pharmacological 
profiles that include actions at multiple receptor targets. 
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Pharmacology of L-Tetrahydropalmatine 
Drug Properties 
Tetrahydropalmatine (THP; C21H25NO4; Chemical name: (13aS)-
2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-
b]isoquinoline; Molecular Weight: 355.43) is a 
tetrahydroprotoberberine (THPB) diisoquinoline alkaloid and a primary 
active constituent of the herbal plant species Stephania rotunda Lour 
(Qianjinteng) and Corydalis ambigua (Yanhusuo). Preparations of 
these plants have been used traditionally for their sedative, 
neuroleptic and analgesic properties [2]. In particular, the levo isomer 
of THP (l-THP; structure shown in Figure 1) appears to contribute to 
many of the therapeutic effects of these herbs [3]. Notably, the dextro 
isomer of THP has distinct pharmacological actions that include 
depletion of monoamines and may contribute to the toxicology profile 
of THP-containing preparations or racemic mixtures of the compound 
[4, 5]. In addition to serving as an active constituent in traditional 
Chinese herbal preparations, purified or synthetic l-THP is approved for 
use and available as Rotundine or Rotundin in China [6] where l-THP 
has been used as an analgesic and sedative for more than 40 years. 
 
Figure 1 Chemical structure of l-THP 
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Metabolism 
The metabolism of l-THP involves demethylation at several sites, 
with a number of demethylated metabolites identified in urine and 
feces [7, 8]. Notably, several of these metabolites can be found in 
Corydalis Yanhusuo and may themselves have actions at dopaminergic 
receptors and other putative l-THP targets [9], thereby contributing to 
the therapeutic effects of l-THP. Further investigation of the 
pharmacological profiles of l-THP metabolites will likely be important to 
fully understanding the mechanisms that contribute to its apparent 
clinical efficacy. 
Pharmacological actions at D1, D2, D3 dopamine and 
other receptors 
Primarily through the efforts of Chinese scientists, most notably led by 
Dr. Jin Guozhang, a researcher at the Shanghai Medical Institute, 
much has been learned about the pharmacological profile of l-THP. A 
large body of evidence suggests that l-THP binds to D1 and D2 
dopamine receptors [10-12]. In contrast to other THPB derivatives, 
which have partial agonist effects at the D1 dopamine receptor, l-THP 
is an antagonist at both of these receptors as defined according to its 
minimal stimulation of cAMP production in D1 receptor-expressing HEK 
cells relative to dopamine ([13] and Mantsch, unpublished results) and 
lack of D2 receptor-mediated mitogenic effects. The Ki values for l-THP 
at D1 and D2 dopamine receptors are approximately 124 nM (D1) and 
388 nM (D2), while the IC50 values are 166 nM (D1) and 1.4 μM (D2), 
respectively (Table 1). The relatively high affinity of l-THP at D1 vs. D2 
receptors, distinguishes it from other available dopamine receptor 
antagonist drugs (e.g., haloperidol). Although l-THP lacks high affinity 
for these receptors, pharmacokinetic data suggest that brain 
concentrations of l-THP that are reached following administration of 
clinically relevant doses are more than sufficient for occupancy [14]. L-
THP also binds to the D3 dopamine receptor ([13] and see Table 1). 
Considering that the D3 receptor has been identified as a target of 
interest for medications aimed at preventing relapse, blockade of D3 
receptors could contribute to the putative utility of l-THP as an anti-
addiction agent [15]. However, the affinity of l-THP for the D3 receptor 
is considerably lower (1.4 μM) than for D1 and D2 receptors, and the 
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IC50 is close to 3.3 μM. Thus, the ability of l-THP to antagonize D3 
receptors at clinically relevant doses is unclear. In addition to the 
antagonism of post-synaptic dopamine receptors, the blockade of pre-
synaptic autoreceptors by l-THP results in increased dopamine release 
[16], and it has been suggested that lower affinity of l-THP for D2 
receptors may confer some degree of autoreceptor selectivity [16, 17].  
 
Table 1 l-THP binding profile at monoaminergic receptors* 
Receptor IC50 (nM ±SEM) Ki (nM ±SEM) Hill Slope ±  
SEM 
Dopamine D1  166 ± 8 124 ± 6 −0.84 ± 0.003 
Dopamine D2  1470 ± 270 388 ± 78 −1.14 ± 0.13 
Dopamine D3  3250 ± 540 1420 ± 220 −1.09 ± 0.14 
5-HT1A  374 ± 69 340 ± 63 −0.86 ± 0.12 
**Adrenergic, α 1  ND ND ND 
***Adrenergic, α 2A  ND ND ND 
*Data from NIDA sponsored drug screening report (to JBW), except noted. 
**shows more than 50% inhibition non-selective binding assay at 10μM [7]. 
***shows more than 50% inhibition binding assay at 10μM [7]. 
ND not determined; SEM standard error of mean 
Along with dopamine receptors, l-THP has been reported to 
interact with a number of other receptor types, including alpha-1 
adrenergic receptors, at which it functions as an antagonist [18], and 
gamma-aminobutyric acid (GABA)A receptors, at which it facilitates 
GABA binding through positive allosteric effects [19]). Additionally, l-
THP displays significant binding to 5-HT1A and alpha-2 adrenergic 
receptors (Table 1). In the case of 5-HT1A receptors, l-THP binds with a 
Ki of approximately 340 nM and has an IC50 of approximately 370 nM, 
concentrations that are likely exceeded in the brain following 
administration of l-THP doses that are active in animal models. 
Rationale for the Use of l-THP for the Treatment of 
Addiction 
The contribution of dopamine to cocaine-seeking behavior is 
well-characterized [20-22]. As a blocker of dopamine uptake [23], 
cocaine increases dopaminergic activity in brain regions critical for 
reinforcement, such as the nucleus accumbens, resulting in stimulation 
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of post-synaptic dopamine receptors and modulation of behavioral 
output from the motive circuit (i.e., drug seeking). Interference with 
the activation of dopamine receptors following cocaine administration 
has long been thought to represent a promising approach for the 
management of cocaine addiction [24]. However, drugs that act as 
pure antagonists at D1 and D2 dopamine receptors have proven to be 
largely ineffective for treating cocaine addicts, due to the high 
incidence of side effects such as sedation and anhedonia and the 
ability of drug users to overcome receptor antagonism by self-
administering greater amounts of cocaine [24]. Like other dopamine 
receptor antagonists, l-THP attenuates locomotor activity [13, 25], 
reduces response rates and breakpoints for sucrose pellet self-
administration [13, 26] and increases thresholds for intracranial self-
stimulation [25] – effects that are highly suggestive of sedative and 
anhedonic properties. However, it has been suggested that, in contrast 
to many other dopamine receptor antagonist drugs, there is separation 
between the doses at which l-THP produces these sedative/anhedonic 
effects and those that are active in preclinical addiction/abuse models, 
suggesting that the pharmacological properties of l-THP may extend 
beyond simple D1/D2 receptor antagonism. Validation of this claim will 
require additional research directly comparing l-THP with other 
dopamine receptor antagonists previously tested for the treatment of 
cocaine addiction (e.g., alpha-flupenthixol) and is critical for 
demonstration that l-THP does not suffer from the same shortcomings 
of these drugs. 
Recent investigation of drugs that target dopaminergic 
neurotransmission has focused on agents that function as partial 
agonists [27, 28], interfere with the activation of D3 dopamine 
receptors [29], or have more complex pharmacological profiles with 
differential actions at multiple receptor types and locations [30, 31]). 
Although other THPB analogs, e.g., levo-stepholidine (l-SPD), have 
been shown to be partial agonists at D1 dopamine receptors [32] it 
has been demonstrated that l-THP has no intrinsic efficacy at D1 
dopamine receptors and therefore likely functions as a D1 receptor 
antagonist [13]. Further, despite some indications that D3 receptor 
antagonism may contribute to the effects of l-THP in preclinical abuse 
models [26] the affinity of l-THP for D3 dopamine receptors is very 
low. Thus, it is possible that actions at non-dopaminergic receptors 
may account for the effects of l-THP. 
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In addition to blocking dopamine clearance through inhibition of 
the dopamine transporter, cocaine prevents uptake of both 
norepinephrine and serotonin, thereby augmenting noradrenergic and 
serotonergic neurotransmission and increasing activation of adrenergic 
and serotonergic receptors [33]. Considering the widespread effects of 
cocaine on monoaminergic neurotransmission, it should not be 
surprising that cocaine addiction is a complex disorder that involves 
actions on and dysregulation of multiple receptors, cell types, and 
neurobiological systems. Implicit in this understanding is the possibility 
that medications that target a single receptor type may not be 
adequate for the management of cocaine addiction. Thus, effective 
pharmacotherapy may require a “cocktail” approach that involves the 
use of more than one medication or drugs such as l-THP with more 
complex pharmacological profiles involving action at multiple 
receptors. An added benefit of such an approach is that it may permit 
additive therapeutic effects while reducing the risk for unwanted side 
effects by minimizing occupation of any single receptor. 
Although there has been much focus on dopamine receptors as 
targets for the development of addiction medications, there is 
considerable evidence that serotonin [34] and norepinephrine [35] can 
also contribute to cocaine’s effects and influence cocaine-seeking 
behavior. For this reason, the ability of l-THP to antagonize cocaine-
induced activation of serotonergic (5-HT), adrenergic and 
dopaminergic receptors may distinguish it from agents with a more 
limited range of action. In particular, secondary effects at alpha-1 and 
5-HT1A receptors, or agonist effects at alpha-2 receptors could 
contribute to the beneficial effects of l-THP against drug relapse. 
Alpha-1 adrenergic {{363 Zhang,X.Y. 2005}} and 5-HT1A [37] 
receptor antagonists and alpha-2 agonists [38] have been previously 
reported to attenuate cocaine seeking in rats. Secondary actions of l-
THP at 5-HT1A and alpha adrenergic receptors could also minimize the 
extrapyramidal effects associated with dopamine receptor antagonism 
by l-THP [39-41]. The contribution of these mechanisms to the effects 
of l-THP will require further investigation. Despite its use as an 
analgesic agent, no interaction of l-THP with opioid receptors has been 
documented, and its analgesic effects are naloxone-independent [42]. 
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Preclinical Studies Of L-Thp 
The idea that l-THP may represent an effective medication for 
treating drug addiction is well-supported by the preclinical animal 
literature (see Table 2 for an overview). A variety of experimental 
approaches are available for examining different aspects of 
abuse/addiction using rodents. Importantly, different assays can be 
used to assess the ability of potential treatments to attenuate the 
positive reinforcing/rewarding effects of cocaine and cocaine relapse. 
One potential issue for interpretation of the actions of l-THP in 
behavioral assays, and a concern about its clinical use, is that the drug 
has known sedative effects that can interfere with behaviors required 
for assessment of drug-seeking behavior. In fact, l-THP has been 
widely used in China for its sedative properties. Accordingly, it has 
been found that l-THP produces dose-dependent reductions in 
locomotor activity and operant responding for non-drug reinforcers in 
rats [13, 26, 43]. For this reason, a critical goal of preclinical testing 
has been to separate non-specific motor suppressive effects of l-THP 
from reductions in drug responsiveness and drug-seeking behavior. 
Table 2 
Effects of l-THP in preclinical behavioral models of cocaine 
abuse/addiction 
Preclinical Model Effects of l-THP References 
FR Cocaine Self-
Administration  
Rightward/downward shift in dose-response  
curve for self-administration 
[14][26] 
PR Cocaine Self-
Administration  
Decreased breakpoints [26][27] 
Drug Discrimination  Rightward shift in dose-response curve [27] 
Intracranial Self-
Stimulation  
Attenuation of cocaine-induced decreases in  
reward threshold 
[26] 
Cocaine-Induced 
Reinstatement  
Decreased reinstatement in response to an  
intraperitoneal cocaine injection 
[14][44] 
Cue-Induced 
Reinstatement  
Decreased reinstatement during response-  
contingent presentation of cocaine-associated  
cues 
[44] 
Stress-Induced 
Reinstatement  
Decreased reinstatement in response to  
footshock stress 
[44] 
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Actions of l-THP on Cocaine Reward/Reinforcement 
The study of the acute positive reinforcing effects of drugs has 
relied heavily on preclinical drug self-administration procedures in 
which rats are surgically implanted with intravenous catheters and 
required to press a lever (or engage in a similar task) in order to 
receive drug infusions. The validity of such procedures arises from the 
observation that, with few exceptions, drugs that are abused by 
humans are also self-administered by rats, while drugs that are not 
abused by people (including l-THP) are not. Compounds that alter drug 
self-administration by rats often do so by reducing the positive 
reinforcing/rewarding effects of drugs and therefore may curb drug 
use by human addicts [44][45]. The most basic self-administration 
approach involves the use of fixed ratio (FR) schedules under which 
drug is delivered every time a rat presses a lever a fixed number of 
times. Two studies by different research groups have demonstrated 
that, in rats trained to self-administer cocaine under FR schedules, l-
THP alters self-administration in a manner that is consistent with a 
reduction in the reinforcing effects of cocaine [13, 25]. Mantsch and 
colleagues reported that, when the effects of l-THP were tested across 
a range of cocaine doses using an approach that involved variation of 
cocaine doses during 30-min components within a single self-
administration session, the dose-response curve for self-administration 
(0.031 – 1 mg/kg/infusion) was shifted downward and to the right by 
l-THP [13]. In the second study by Xi and colleagues [25], it was 
found that, when rats were tested for self-administration at a single 
higher cocaine dose (0.5 mg/kg/infusion) in the absence of prior 
variation in the self-administered cocaine dose, l-THP dose-
dependently increased responding, a behavioral pattern that is 
associated with a reduction in the reinforcing effects of cocaine when 
observed under these conditions. Notably, in these studies, l-THP was 
effective at doses that failed to alter concurrently-measured [13] or 
independently-measured [25]food-reinforced responding under 
identical schedules of reinforcement. 
A second protocol for examining treatment effects on positive 
reinforcement by cocaine involves the use of progressive ratio (PR) 
schedules of cocaine self-administration, under which the response 
requirement for cocaine delivery progressively increases with each 
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successive cocaine infusion. Using this approach, the ability of a 
medication to reduce cocaine’s reinforcing efficacy and/or the 
motivation to acquire cocaine can be assessed according to changes in 
the breakpoint for self-administration, defined as the maximal amount 
of work (i.e., lever presses or nose pokes) that the subject will 
perform in order to receive the drug [46][47]. Increases and 
decreases in breakpoints (i.e., a greater or lesser amount of work 
performed to receive the drug) are interpreted as elevations and 
reductions in reinforcing efficacy and/or motivation to take the drug, 
respectively. It has been suggested that PR schedules offer an 
advantage over FR schedules for the determination of changes in 
reinforcing efficacy, due to reduced susceptibility to the rate-
decreasing (e.g., sedative) effects of drugs and relative ease of 
interpretation of findings. L-THP has been reported by two separate 
research groups to reduce breakpoints for cocaine self-administration 
in rats at doses that fail to alter PR self-administration of a food 
reinforcer [25, 26]. When combined with the findings from studies 
investigating the effects of l-THP on cocaine self-administration under 
FR schedules of reinforcement, these data suggest that l-THP 
effectively reduces the reinforcing properties of cocaine, thus 
potentially curbing use. 
Alterations in the rewarding effects of cocaine can also be 
studied using an intracranial self-stimulation (ICSS) approach [48]. 
With this method, an electrode is implanted into the brain to permit 
stimulation of neural pathways subserving reward/reinforcement. 
Implanted rats will repeatedly press a lever in order to receive 
stimulation. Drugs of abuse such as cocaine will increase sensitivity of 
rats to stimulation, as demonstrated by a reduction in the threshold 
current for ICSS. L-THP blocks cocaine-induced decreases in ICSS 
thresholds at doses that alone fail to increase threshold in a manner 
indicative of anhedonic effects [25]. Although these findings suggest 
that l-THP does not produce anhedonic effects at doses that can 
mitigate cocaine’s effects, it should be noted that effects on ICSS 
thresholds in rats with a history of cocaine self-administration have not 
been assessed. 
Yet another common method for the examining the ability of 
treatments to interfere with abuse-related drug effects is the drug 
discrimination protocol [49]. Using this approach, rats learn to 
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recognize the interoceptive, subjective state (i.e., discriminative 
stimulus) produced by cocaine and are trained to emit distinct 
response patterns in the presence and absence of cocaine delivery. As 
is the case with the reinforcing effects of cocaine, l-THP blocks 
cocaine’s discriminative stimulus effects, as observed as a rightward 
shift in the dose response curve for cocaine substitution for the 
training dose [8]. Also as is observed with the reinforcing effects of 
cocaine, l-THP attenuates cocaine discrimination at doses that fail to 
produce suppression of response rate [26]. 
Effects of l-THP in Preclinical Models of Relapse 
Although the ability to competitively block cocaine’s acute 
subjective and positive reinforcing/rewarding effects may alter use 
patterns, it is unlikely that this, by itself, will lead to sustained drug 
abstinence. Many addicts enter into treatment during periods of 
abstinence in order to prevent drug relapse, which is typically 
preceded by craving, or the intense desire to use a drug. A variation of 
the self-administration protocol, the reinstatement paradigm, can be 
used to study stimuli that induce drug relapse [50]. Using this 
approach, relapse can be examined based on the ability of stimuli 
reinstate or restore extinguished drug-seeking behavior after it has 
been extinguished. Notably, the same stimuli that produce craving and 
relapse in humans (drug re-exposure, stress, and exposure to drug-
associated cues) also reinstate extinguished cocaine-seeking behavior 
in rats [51]. Importantly, the neurobiological substrates that underlie 
reinstatement appear to be distinct from those that mediate the 
subjective and positive reinforcing/rewarding effects of cocaine. L-THP, 
administered ip [13] or orally [43] attenuates reinstatement of 
extinguished cocaine seeking in rats in response to a cocaine 
challenge, a stressful stimulus (uncontrollable electric footshock), or 
response-contingent exposure to a stimulus (tone and light complex) 
previously associated with drug delivery in rats. This attenuation was 
observed at l-THP doses that failed to alter lever-pressing for a non-
drug (i.e., food) reinforcer when tested either concurrently with 
reinstatement or in separate groups of rats. 
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Clinical Use and Studies Of L-Thp 
Pharmacokinetics of l-THP 
The pharmacokinetic properties of l-THP are favorable for its 
development as an anti-addiction medication. Plasma and tissue levels 
of l-THP can be quantified using HPLC. It is well absorbed following 
oral administration in both rat and man [14, 52]. In rats, following oral 
administration of racemic THP or l-THP, blood levels of l-THP show a 
rapid peak within the first hour, followed by a gradual decline, 
resulting in a t1/2 of approximately 5 hours [14]. The half-life for l-THP 
in man appears to be about 10 hours [53][54], permitting once daily 
dosing. L-THP also readily enters the brain [14] with peak levels within 
the first hour followed by stable concentrations measured in a number 
of brain regions, including the striatum, for the next 4-6 hrs. The 
effects of l-THP on cytochrome P450 mediated metabolism of other 
drugs appears to be minimal and primarily involve low affinity 
inhibition of CYP2D6 [55]. 
Clinical Uses in China 
It has long been recognized that l-THP has therapeutic value for 
treating a number of CNS-related conditions. The effectiveness of l-
THP as a non-opioid analgesic and sedative/anxiolytic agent resulted in 
the approval of purified l-THP for this indication by the Chinese SFDA 
(FDA equivalent) and has led to extensive investigation of the 
pharmacological properties of l-THP. The suggestion that the 
therapeutic effects of l-THP may be partly attributable to dopamine 
receptor antagonism [42, 56] has led to the investigation of the 
potential utility of l-THP for other disorders known to be associated 
with dopaminergic dysfunction, particularly drug addiction. Interest in 
l-THP as a medication for treating addiction has peaked with recent 
preliminary clinical trials in China that found that l-THP reduces drug 
craving and relapse [15] and promotes detoxification [16] in 
recovering heroin addicts. 
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Clinical Studies in Heroin-Dependent Populations 
Although clinical trials examining the potential utility of l-THP for 
cocaine addiction have not been conducted, the results of studies 
testing for effectiveness in heroin-dependent populations have been 
promising. A pilot study testing for the effects of l-THP in heroin users 
[57] examined the efficacy of l-THP in reducing craving and relapse 
rate in 120 heroin addicts (average of 2-3 heroin uses per day for 
about 3 years). In this randomized, double-blind, placebo-controlled 
study, patients received 4 weeks of l-THP treatment and three months 
follow-up after l-THP treatment during which the severity of the 
protracted abstinence (a.k.a., post-acute) withdrawal syndrome 
(PAWS), as measured using a Heroin Withdrawal Scale (HWC) 
questionnaire, and abstinence rate, determined based on drug-positive 
urine tested, were assessed. The HWC questionnaire consisted of self-
rating on a 5-point scale of 30 different symptoms in four different 
categories: mood, craving, insomnia, and somatic symptoms. The 
treatment group had significantly lower overall PAWS scores, with 
reductions in somatic symptoms and insomnia and, especially, in 
craving (3.5 for treatment group vs. 7.0 for placebo group) as well as 
a three-fold higher abstinence rate (47.8%) relative to the placebo 
control group (15.2%). No hepatic toxicity was reported. 
A second human study [58] examined the therapeutic effect of 
l-THP combined with methadone for heroin detoxification. Sixty 
patients were randomly divided into two groups: one received 
methadone plus l-THP; the other received methadone only. The 
primary outcome measures were total amount of methadone used 
during detoxification and days of detoxification. The combined 
treatment group achieved a 96% rate of successful detoxification, 
compared to 73% for the methadone alone group. The combined 
group also used significantly less total methadone (275 mg vs. 415 
mg) and needed less days for the detoxification treatment (8 days vs. 
12 days). 
Although the effects of l-THP in cocaine-addicted populations 
has not yet been studied, due primarily to the lack of approval for 
testing in the U.S., these human studies, when considered along with 
our preclinical studies, provide compelling evidence to support the use 
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of l-THP as an effective new medication for the treatment of drug 
addiction with a non-opioid mechanism and anti-craving efficacy. 
Safety Profile 
The availability of l-THP on the Chinese market since the early 
1960’s and its widespread use in a variety of patient populations, as 
well as its regulation by the Chinese SFDA, should position l-THP as a 
safe medication rather than as an unregulated and potentially 
dangerous botanical product. According to the Chinese pharmacopeia 
[6] and drug labeling, l-THP is safe at the recommended therapeutic 
dosage range (60-180 mg). At higher doses, adverse effects include 
sleepiness, dizziness, and nausea. Overdose can cause respiratory 
inhibition and, consistent with other drugs with dopamine receptor 
antagonist properties, extrapyramidal symptoms. There appears to be 
only a few reported cases of allergic reactions upon the use of l-THP. 
Despite its longstanding safety record in China, some l-THP containing 
preparations, most notably Jin Bu Huan, an adulterated herbal 
product, are currently banned by the FDA for human consumption in 
the US due to concerns about toxicity [59, 60]. However, reports of 
hepatitis [60, 61] and CNS depression [59] related to the l-THP 
containing preparation, Jin Bu Huan, were likely related, in part, to 
contamination and improper use issues common to many unregulated 
herbal products. Final determination of the safety of l-THP awaits more 
methodical testing of the effects of standardized doses of purified l-
THP. Accordingly, there has been a recent push towards re-evaluation 
of l-THP by the FDA. 
Future Perspective 
Although the results from preclinical experiments and 
preliminary Chinese clinical trials suggest that l-THP has great 
potential for the treatment of cocaine addiction, there are a number of 
obstacles that must be overcome before l-THP can be considered for 
approved use in cocaine-dependent populations in the United States. 
Foremost among these are concerns about the safety of l-THP, which 
are largely secondary to issues with l-THP containing botanical 
preparations and known problems with previously evaluated dopamine 
antagonist drugs. In the former case, distancing the safety profile of l-
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THP from those of unregulated botanical preparations while leveraging 
the large body of available evidence that has been accumulated across 
years of approved and regulated use of Rotundine in China is critical. 
Notably, while the clinical data from China provide important “proof of 
concept” of l-THP’s efficacy and indication of its safety, additional 
testing in man consistent with FDA standards will be essential. This 
will, of course, require the approval of l-THP as a new investigational 
drug by FDA. With regards to concerns about dopamine antagonist 
drugs that have been previously advanced as potential anti-addiction 
medications, further evidence to support the claim that l-THP is 
distinct from and superior to these drugs (e.g., alpha-flupenthixol) is 
needed. Although there are some indications that the pharmacological 
profile of l-THP is unique and positively distinguishes it from other 
dopamine antagonist drugs in terms of safety and efficacy, our 
understanding of the mechanisms of action of l-THP remains 
somewhat limited. In particular, side-by-side comparison with other 
dopamine antagonist drugs is needed in order to more convincingly 
make the case that l-THP does not share the shortcomings (e.g., 
extrapyramidal effects, sedation) that have prevented their approval 
as anti-addiction medications. 
In the event that l-THP does not receive FDA approval, there is 
still much to be learned from its unique pharmacological mechanisms. 
At minimum, the demonstrated efficacy of l-THP in preclinical models 
and clinical studies suggests that the development or identification of 
compounds with more complex pharmacological effects that include 
actions at multiple monoamine receptors (not just D1 and D2 
dopamine receptors) or the formulation of “drug cocktail” approaches 
may represent promising new strategies for the treatment of addiction. 
Interestingly, l-THP represents just one of series of naturally-occurring 
tetrahydroprotoberberine compounds with similar pharmacological 
profiles. Compounds such as l-SPD, which has a similar binding profile 
as l-THP but functions as a partial agonist at D1 dopamine receptors 
[32] may serve as provocative new platforms for development as anti-
addiction medications and, along with l-THP, could provide starting 
points for targeted redesign using medicinal chemistry. 
Finally, the extant data supporting the use of l-THP (and related 
compounds) for the treatment of cocaine addiction suggest potential 
utility for the pharmacological management of addiction to other drugs 
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of abuse. Indeed, clinical trials demonstrating efficacy in recovering 
heroin addicts [57, 58] along with studies showing efficacy in 
preclinical models of opiate abuse [62] suggest that l-THP may be 
effective for treating addiction to heroin. Studies examining its 
potential use in other addiction populations (alcohol, nicotine) are 
currently ongoing and should provide additional understanding about 
the therapeutic utility of l-THP in the near future. 
Executive Summary 
Treatment of Cocaine Addiction 
 Despite its societal impact, cocaine addiction persists as a 
serious medical condition for which no FDA-approved medication 
exists. 
 An ideal medication for treating addiction should attenuate 
cocaine’s rewarding effects and at the same time reduce drug 
craving, thus preventing relapse. 
 The multifaceted nature of cocaine addiction and its underlying 
neurobiology suggests that multiple-drug (“cocktail”) therapy or 
compounds with more complex pharmacological profiles will be 
necessary for effective treatment. 
Pharmacology of L-Tetrahydropalmatine 
 The tetrahydroprotoberberine, l-THP, has a pharmacokinetic and 
pharmacological profile that may be optimal for treating cocaine 
addiction. 
 The pharmacological profile of l-THP includes antagonism of 
dopamine D1, and D2 receptors as well as actions at dopamine 
D3, alpha adrenergic and serotonin receptors. 
Preclinical Studies of L-THP 
 l-THP is effective in preclinical models that examine effects on 
the reinforcing/rewarding/subjective effects of cocaine as well as 
in models of relapse. 
 In these preclinical models, l-THP is effective at doses that fail 
to produce non-specific motor impairment and/or sedation. 
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Clinical Use and Studies Of L-THP 
 L-THP has a pharmacokinetic profile that is favorable for clinical 
use. 
 l-THP has a long-standing record of safe use in China for a 
number of indications under the trade-name Rotundine. 
 Concerns about liver toxicity and sedation associated with the 
use of some l-THP containing herbal preparations in the US are 
likely due to poor quality and improper use of these unregulated 
products. 
 Preliminary clinical studies investigating the effects of l-THP in 
human heroin addict populations have yielded promising results. 
 Additional clinical examination of the efficacy of l-THP in human 
cocaine addict populations is needed. 
 Testing in human populations in the US awaits further 
demonstration to the FDA that l-THP is safe for human 
consumption at doses that effectively manage addiction. 
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